Crucial Differences in the Mechanism of Action of Cell Transplantation and (Chemical) Drug Therapy
Cell transplantation is a vastly different approach to medical therapy and cannot be immediately understood by mind accustomed to deal with (chemical) drug therapy.
In order to comprehend this statement, you should visualize that
Every cell in your body is programmed to die, and it does so before you die. (The sole exception may be certain neurons.)
All cells of our body are being continuously replaced, albeit each kind with different speed.
In every disease the principal cells of a diseased organ(s) die faster than the sick body is able to replace them.
When the quantity of principal cells of a diseased organ(s) drops below certain limit, such organ(s) dies.
If it is a vitally important organ, without which one cannot live, such as heart, or brain, for example, and surgeons cannot replace such a dying organ(s), the sick organism will die, too.
Current medicine knows of one treatment only when it becomes mandatory to replace dead cells, tissues, or organs: transplantation.
Transplantation of organs from human donors, such as heart, kidney, liver, etc., have become fairly common nowadays. These are life saving major surgical procedures, usually carried out as a 'treatment of last resort'.
Besides the surgical risk, there is always a problem of rejection: the body of the recipient patient rejects transplanted organ from another body with guarantee, and the only way to prevent it is by taking immunosuppressants for the rest of patients life. These drugs can stop a rejection for some time, but only at the expense of serious, often life-endangering, complications.
Some organs cannot be transplanted, such as brain, immune system, so that many diseases cannot be treated by organ transplantation.
BCRO fetal precursor cell transplantation has historically preceded organ transplantation by several decades. It will dominate the medicine of 21st century. The main reasons for such statements are:
The therapeutic effect of drugs of chemical origin is not as broad as those of any of the 200+ known types of cells transplantated into a body with insufficient quantity or quality of a particular cell type(s).
Drugs of chemical origin are used to modify a specific function, and their effect is usually narrowly focused.
You should be aware that there are two schools of medical thought in the field of BCRO type cell transplantation today:
According to the German school, cell transplant's combination(s) used for the treatment of complications of type 1 diabetes mellitus is different from that used for a patient with complications of type 2 diabetes mellitus.
A patient with complications of type 2 diabetes mellitus can be successfully treated by cell transplantation also(!), with the exception of significantly obese patients in whom the treatment of obesity has been repeatedly unsuccessful.
The German school does agree with the U.S. school in some clinical situations, such as for example in cases where the patient is a small child that just became ill with type 1 diabetes mellitus: the treatment by implanting of pancreatic islet cells only would be perfectly adequate here.
BCRO clinical method of cell transplantation based on the German school requires that the treatment be 'individualized' by 'tailoring' the combination of cell transplants to a specific disease of a specific patient.
Under the Oath of Hippocrates physicians should treat their patients the best way they know how.
When the disease(s) of a specific patient requires and responds to drugs of chemical origin, he should be treated that way, when patient's disease(s) requires and responds to cell transplantation, there should be no hesitation to use such a treatment, and when a combination of both is necessary, so be it.
There are no incurable diseases only those that we do not know how to cure yet. Given the opportunity the cell transplantation will lower the number of incurable diseases.
|ABOUT BCRO||WARRANTY/REPLACEMENT||DISCLAIMER||PRIVACY STATEMENT|
|Copyright Stem Cell Transplantation Ltd.|
|Updated: December 2018|